Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization

Journal of the American College of Cardiology

Volumn 57, Issue 21, 2011, Pages 2143-2151

  Rber, Lorenz ^a   Jni, Peter ^a,b   Nesch, Eveline ^b   Kalesan, Bindu ^b   Wenaweser, Peter ^a   Moschovitis, Aris ^a   Khattab, Ahmed A ^a   Bahlo, Maryam ^a   Togni, Mario ^a   Cook, Stphane ^a   Vogel, Rolf ^a   Seiler, Christian ^a   Meier, Bernhard ^a   Windecker, Stephan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

coronary disease; drug eluting stents; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; INSULIN; ORAL ANTIDIABETIC AGENT; PROTON PUMP INHIBITOR; RAPAMYCIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79956142994     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.01.023     Document Type: Article

References (23)

1. J.W. Moses, M.B. Leon, and J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323 (Pubitemid 37186209)
2. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231 (Pubitemid 38067635)
3. C. Stettler, S. Wandel, and S. Allemann Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 370 2007 937 948 (Pubitemid 47393576)
4. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice Lancet 369 2007 667 678 (Pubitemid 46281313)
5. R.A. Byrne, R. Iijima, and J. Mehilli Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer J Am Coll Cardiol Intv 2 2009 291 299
6. L. Rber, and S. Windecker Current status of drug-eluting stents Cardiovasc Ther 2010 Mar 27 [E-pub ahead of print]
7. P.W. Serruys, P. Ruygrok, and J. Neuzner A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent EuroIntervention 2 2006 286 294
8. G.W. Stone, M. Midei, and W. Newman Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease JAMA 299 2008 1903 1913 (Pubitemid 351574920)
9. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice Lancet 375 2010 201 209
10. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 362:166374.
11. A. Schomig, A. Dibra, and S. Windecker A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease J Am Coll Cardiol 50 2007 1373 1380 (Pubitemid 47449734)
12. D.E. Kandzari, M.B. Leon, and J.J. Popma Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease J Am Coll Cardiol 48 2006 2440 2447 (Pubitemid 44881222)
13. Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care Lancet 375:10909.
14. S. Windecker, A. Remondino, and F.R. Eberli Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization N Engl J Med 353 2005 653 662 (Pubitemid 41175673)
15. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
16. S. Windecker, and P. Juni The drug-eluting stent saga Circulation 10 2009 680 686
17. J. Daemen, and P.W. Serruys Drug-eluting stent update 2007: part I: a survey of current and future generation drug-eluting stents Circulation 116 2007 316 328 (Pubitemid 47196568)
18. G.D. Curfman, S. Morrissey, J.A. Jarcho, and J.M. Drazen Drug-eluting coronary stentspromise and uncertainty N Engl J Med 356 2007 1059 1060
19. P. Wenaweser, J. Daemen, and M. Zwahlen Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice J Am Coll Cardiol 52 2008 1134 1140
20. C. Stettler, S. Allemann, and S. Wandel Drug eluting and bare metal stents in people with and without diabetes BMJ 337 2008 a1331
21. Y. Onuma, N. Kukreja, and N. Piazza The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH registry J Am Coll Cardiol 54 2009 269 276
22. Byrne RA. Two-year outcomes after everolimus- or sirolimus-eluting stents in patients with coronary artery disease in the ISAR TEST 4 Trial. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 24, 2010; Washington, DC.
23. Okkels Jensen L. Randomised comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 24, 2010; Washington, DC.